These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 18091347)

  • 1. High levels of serum prostaglandin E2 in children with osteogenesis imperfecta are reduced by neridronate treatment.
    D'Eufemia P; Finocchiaro R; Celli M; Zambrano A; Tetti M; Villani C; Persiani P; Mari E; Zicari A
    Pediatr Res; 2008 Feb; 63(2):203-6. PubMed ID: 18091347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of plasma taurine level in children affected by osteogenesis imperfecta during bisphosphonate therapy.
    D'Eufemia P; Finocchiaro R; Zambrano A; Tetti M; Ferrucci V; Celli M
    Biomed Pharmacother; 2007 May; 61(4):235-40. PubMed ID: 17275249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta.
    Weber M; Roschger P; Fratzl-Zelman N; Schöberl T; Rauch F; Glorieux FH; Fratzl P; Klaushofer K
    Bone; 2006 Sep; 39(3):616-22. PubMed ID: 16644299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired bone remodeling in children with osteogenesis imperfecta treated and untreated with bisphosphonates: the role of DKK1, RANKL, and TNF-α.
    Brunetti G; Papadia F; Tummolo A; Fischetto R; Nicastro F; Piacente L; Ventura A; Mori G; Oranger A; Gigante I; Colucci S; Ciccarelli M; Grano M; Cavallo L; Delvecchio M; Faienza MF
    Osteoporos Int; 2016 Jul; 27(7):2355-2365. PubMed ID: 26856585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum brain-type creatine kinase increases in children with osteogenesis imperfecta during neridronate treatment.
    D'Eufemia P; Finocchiaro R; Villani C; Zambrano A; Lodato V; Palombaro M; Properzi E; Celli M
    Pediatr Res; 2014 May; 75(5):626-30. PubMed ID: 24518563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decrease of serum alkaline phosphatase after three cycles of pamidronate disodium in children with severe osteogenesis imperfecta.
    Cabral de Menezes Filho H; Rodrigues JM; Radonsky V; Della Manna T; Kuperman H; Steinmetz L; Dichtchekenian V; Damiani D; Setian N
    Horm Res; 2007; 68 Suppl 5():207-8. PubMed ID: 18174750
    [No Abstract]   [Full Text] [Related]  

  • 7. Alendronate treatment in children with osteogenesis imperfecta.
    Akcay T; Turan S; Guran T; Bereket A
    Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of osteogenesis imperfecta with bisphosphonates].
    Tau C
    Medicina (B Aires); 2007; 67(4):389-95. PubMed ID: 17891938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience with bisphosphonates in osteogenesis imperfecta.
    Glorieux FH
    Pediatrics; 2007 Mar; 119 Suppl 2():S163-5. PubMed ID: 17332237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta.
    Löwing K; Aström E; Oscarsson KA; Söderhäll S; Eliasson AC
    Acta Paediatr; 2007 Aug; 96(8):1180-3. PubMed ID: 17578486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonate treatment in osteogenesis imperfecta: which drug, for whom, for how long?
    Rauch F; Glorieux FH
    Ann Med; 2005; 37(4):295-302. PubMed ID: 16019729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of bisphosphonates on tooth eruption in children with osteogenesis imperfecta.
    Kamoun-Goldrat A; Ginisty D; Le Merrer M
    Eur J Oral Sci; 2008 Jun; 116(3):195-8. PubMed ID: 18471236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteogenesis imperfecta, current and future medical treatment.
    Rauch F; Glorieux FH
    Am J Med Genet C Semin Med Genet; 2005 Nov; 139C(1):31-7. PubMed ID: 16278881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates.
    Malmgren B; Aström E; Söderhäll S
    J Oral Pathol Med; 2008 Apr; 37(4):196-200. PubMed ID: 18321345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous pamidronate in osteogenesis imperfecta type VII.
    Cheung MS; Glorieux FH; Rauch F
    Calcif Tissue Int; 2009 Mar; 84(3):203-9. PubMed ID: 19137231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose intravenous pamidronate treatment in osteogenesis imperfecta.
    Gökşen D; Coker M; Darcan S; Köse T; Kara S
    Turk J Pediatr; 2006; 48(2):124-9. PubMed ID: 16848111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of bisphosphonates in children with osteogenesis imperfecta.
    Glorieux FH
    J Pediatr Endocrinol Metab; 2001; 14 Suppl 6():1491-5. PubMed ID: 11837505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum creatine kinase isoenzymes in children with osteogenesis imperfecta.
    D'Eufemia P; Finocchiaro R; Zambrano A; Lodato V; Celli L; Finocchiaro S; Persiani P; Turchetti A; Celli M
    Osteoporos Int; 2017 Jan; 28(1):339-346. PubMed ID: 27562566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oesteogenesis imperfecta--genetics, diagnosis and medical treatment].
    Brixen KT; Illum NO; Hansen B; Lund AM; Mosekilde L
    Ugeskr Laeger; 2007 Jan; 169(1):30-4. PubMed ID: 17217883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term Effects of Neridronate in Adults with Osteogenesis Imperfecta: An Observational Three-Year Italian Study.
    Viapiana O; Idolazzi L; Fassio A; Orsolini G; Rossini M; Adami G; Bertoldo F; Gatti D
    Calcif Tissue Int; 2017 Apr; 100(4):341-347. PubMed ID: 28130572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.